ARTICLE | Clinical News
Custirsen sodium regulatory update
September 1, 2008 7:00 AM UTC
FDA granted Fast Track designation to OGX-011 for use in combination with docetaxel to treat progressive metastatic prostate cancer. The second-generation antisense inhibitor of clusterin mRNA is in ...